The way to silence a killer is to make some noise.

Cancer kills more than 1,500 people every day. And it is the leading cause of death by disease in our children. Yet, for every ten dollars in taxes the government collects, it spends only one penny on cancer research. We can do better. For the more than eight million Americans now living with cancer - and for the millions more at risk - we must do better. THE MARCH is a momentous event uniting people in Washington, DC, and in communities across the nation. We are coming together to make cancer the nation's #1 research priority. We are raising our voices to say No more... No more suffering... No more excuses... No more cancer. Please join us.

THE SIDNEY KIMMEL FOUNDATION for CANCER RESEARCH

The AACR is a proud supporter of The March. For information about AACR members' March-related activities, please call the AACR Office at (215) 440-9300.
Editor-in-Chief
John Mendelsohn
Growth factors, hormones, cell growth; radiation therapy, surgery, subspecialty investigation

Deputy Editor
Waan Ki Hong
Clinical trials targeted at specific malignancies, chemoprevention

Senior Editors
Bruce A. Chabner
Clinical pharmacology and pharmacokinetics, drug metabolism, drug sensitivity and resistance, drug interactions
Michael B. Kastan
Cell cycle regulation, cell death
Lance A. Liotta
Pathology, metastasis
David Sidransky
Molecular pathogenesis, molecular correlates

Paul Sondel
Immunotherapy and cytokines—preclinical, and clinical trials

Beverly A. Teicher
Experimental therapeutics, preclinical pharmacology, combined modality regimens, animal therapy models

Jeffrey M. Trent
Genetics, cytogenetics

Associate Editors
Martin D. Abeloff
Carmen J. Allegra
Laurence H. Baker
Charles M. Balch
Barthel Banlogie
Robert C. Bast, Jr.
Colin B. Begg
Joseph R. Bertino
Ronald H. Blum
George J. Bosl
Paul A. Bunn, Jr.
Michael A. Caligiuri
Alfred E. Chang
Paul B. Chapman
Michael C. Christian
Curt I. Civin
Ronald Crystal
William S. Darlton
Albert B. Deisseroth
Patricia K. Donahoe
Ross C. Donehower
Timothy J. Eberlein
Merrill J. Egorin
Frederick R. Eibler
Robert M. Elumhof
Paul F. Engstrom
Eric R. Fearon
Isaiah J. Fidler
Richard M. Fox
Michael A. Friedman
Zvi Y. Fuks
Stephen L. George
Giuseppe Giaccone
Luca Gianni
Anna Giuliano
Eli Glazstein
David W. Golde
Mark R. Green
Jerome E. Groopman
William N. Hait
Adrian L. Harris
Curtis C. Harris
Sandra J. Horning
William J. Hoskins
Janet A. Houghton
Stephen B. Howell
Daniel C. Ilhe
John T. Isaacs
Robert B. Jenkins
David H. Johnson
V. Craig Jordan
Barton A. Kamen
S. B. Kaye
David P. Kelsey

David Khayat
John M. Kirkwood
Donald W. Kufe
Steven M. Larson
John S. Lazo
Victor A. Levin
Marc E. Lippman
Edison T. Liu
Patrick J. Loehrer, Sr.
Dan L. Longo
Michael T. Lotze
Maurie Markman
William P. McGuire III
Roland Mertelsmann
Frank L. Meykens, Jr.
John D. Minna
Bruce Minsky
Monica Morrow
James L. Mulshine
Sharon B. Murphy
Charles E. Myers
Larry Norton
Richard J. O'Reilly
Robert F. Ozols
Ira Pastan
William P. Peters

Herbert M. Pinedo
Philip A. Pizzo
William K. Plunkett
Jerome B. Posner
Derek Ragha
Mark J. Ratain
John C. Reed
Ralph A. Reisfeld
Jerome Ritz
Jack A. Roth
Eric B. Rowinsky
Edward A. Sausvick
Howard I. Scher
Richard L. Schilsky
Richard M. Simon
John F. Smyth
Jeffrey A. Sosman
Michael B. Sporn
Louise C. Strong
Masaaki Terada
Daniel V. Von Hoff
Raymond P. Warrell, Jr.
Jane Weeks
Ralph R. Weichselbaum
Theresa L. Whiteside
Leonard A. Zeliging

AACR Publications Department
Public Ledger Building, Suite 826
150 South Independence Mall West
Philadelphia, PA 19106-3483
Phone: (215) 440-9344
FAX: (215) 440-9354
E-mail: pubs@aacr.org

Editorial Office
Colleen M. Hubona, Executive Editor, Department of Educational Publishing Services—227, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030 Phone: (713) 792-6014; Fax: (713) 792-6016

Accelerated mailing of all AACR journals to AACR members in Japan is supported by a generous grant from the Bayer Pharmaceutical Company, Tsukuba, Japan. One-year subscriptions to Clinical Cancer Research are made available to third-year hematolagy/oncology fellows in the United States through the generous support of Rhone-Poulenc Rorer Oncology.

Clinical Cancer Research is published monthly, one volume per year, by the American Association for Cancer Research, Inc. (AACR). Except for members of the AACR, all subscriptions are payable in advance to AACR. Subscription Office, P.O. Box 11806, Birmingham, AL 35202 (Phone: (800) 633-4931 or (205) 995-1567; FAX: (205) 995-1568), to which all business communications, remittances (in United States currency or its equivalent), and subscription orders should be sent. In Japan, send orders and inquiries to (sole agent): USACO Corporation, Tsujita Bldg., 13F, Shimbashi 1-chome, Minato-ku, Tokyo 105, Japan, Tel (03) 502-6671. Individuals who are not AACR members may subscribe to Volume 4 (1998) of Clinical Cancer Research at the rate of $230 U.S./$525 foreign. Clinical Cancer Research is available to institutions as a combined subscription with Cancer Research. The combined 1998 institutional subscription price of $750 U.S./$925 foreign includes $230 U.S./$525 foreign for subscription to Clinical Cancer Research. Foreign subscription cost includes cost of surface mail. For faster delivery, expedited mailing rates are available by contacting the AACR Publications Department. Canadian subscribers should add 7% GST. Changes of address notification should be sent 60 days in advance and include both old and new addresses. Member subscribers should send address changes to: AACR Member Services, Public Ledger Bldg., Suite 826, 150 South Independence Mall West, Philadelphia, PA 19106-3483. Nonmember subscribers should send changes of address to: AACR Subscription Office, P.O. Box 11806, Birmingham, AL 35202. Copies of the journal which are undeliverable because of address changes will be destroyed.
Notice to Members of the American Association for Cancer Research (AACR)

Officers for 1998–1999

President: Webster K. Cavenee, Ludwig Institute for Cancer Research, La Jolla, CA 92039-0660
President-Elect: Daniel D. Von Hoff, Institute for Drug Development, San Antonio, TX 78245
Treasurer: Bayard D. Clarkson, Memorial Sloan-Kettering Cancer Center, New York, NY 10021
Executive Director: Margaret Foti, AACR, Public Ledger Bldg., Suite 826, Philadelphia, PA 19106-3483

Annual Dues

The annual dues of active members of the AACR are $175, $50 of which may be applied to a subscription to Clinical Cancer Research. Corresponding members of the Association will be charged an appropriate fee to offset periodicals postage costs. Payment of dues and changes of address of members of the Association should be sent promptly to Margaret Foti, Executive Director, AACR, Public Ledger Bldg., Suite 826, 150 South Independence Mall West, Philadelphia, PA 19106-3483; Phone: (215) 440-9300; FAX: (215) 440-9313.

Submission of Manuscripts

Clinical Cancer Research, a journal of the American Association for Cancer Research, publishes original articles describing clinical research on the cellular and molecular characterization, prevention, diagnosis, and therapy of human cancer. Its focus is on innovative clinical research and translational research which bridges the laboratory and the clinic. Clinical Cancer Research is especially interested in clinical trials evaluating new treatments for cancer; research on molecular abnormalities that predict incidence, response to therapy, and outcome; and laboratory studies of new drugs and biological agents that will lead to clinical trials in patients. All submissions undergo peer review. Papers should be sent directly to an appropriate Senior Editor or to the Editor-in-Chief for review. See “Instructions for Authors” (page ii of this issue) for complete mailing addresses of the Editor-in-Chief, Deputy Editor, and Senior Editors.

Back Issues and Single Copy Sales of the Journal

Copies of back stock of the journal may be ordered from AACR Subscription Office, P.O. Box 11806, Birmingham, AL 35202 [Phone: (800) 633-4931 or (205) 995-1567; FAX: (205) 995-1588]. As long as supplies permit, single copies will be sold by this company at $25.00/copy. Orders outside the U.S. add $3/copy to offset postage costs.

Advertisements

Advertisement insertion orders and copy must be received one month prior to the date of issue in which the advertisement is to be published. The journal is mailed on approximately the 1st day of the month of issue. Inquiries about advertising should be directed to: M. J. Mrvica Associates, Inc., 2 West Taunton Ave., Berlin, NJ 08009 [Telephone: (609) 768-9360; FAX: (609) 753-0064].

Copyright and Permissions

Authors who wish to publish in Clinical Cancer Research must formally transfer copyright to the proprietor of the journal, the American Association for Cancer Research, Inc. It is understood by this transfer that the authors relinquish all exclusive rights of copyright ownership, including the rights of reproduction, derivation, distribution, sale, and display.

Authors who prepared their articles as part of their official duties as employees of the U.S. Federal Government are not required to transfer copyright to the American Association for Cancer Research, Inc., since these articles are considered to be in the public domain. In the case of articles supported by federal grants or contracts, copyright transfer to the American Association for Cancer Research, Inc., is required. The federal government may retain a nonexclusive license to publish or republish such material.

The Journal will routinely allow authors (or others with the permission of the authors) to include select parts of a copyrighted article in reviews, books, or subsequent papers, upon written request to the AACR Director of Publications. Requests to reproduce an article in its entirety will be considered on an individual basis and permission may be granted contingent upon payment of an appropriate copyright fee. All reproduction requests must include a brief description of intended use and a stamped, self-addressed envelope. Third parties should obtain the approval of the authors before corresponding with the AACR.

Those who wish to photocopy articles should contact the AACR Publications Department [Phone: (215) 440-9300; FAX: (215) 440-9354].

No responsibility is accepted by the Editors, by the American Association for Cancer Research, Inc., or by Cadmus Journal Services for the opinions expressed by contributors or for the content of the advertisements.

Clinical Cancer Research is abstracted and/or indexed in Cancer Lit, Chemical Abstracts, Current Contents/Clinical Medicine, and Index Medicus/MEDLINE.

Clinical Cancer Research (ISSN 1078-0432) is published monthly by the American Association for Cancer Research, Inc., Public Ledger Bldg., Suite 826, 150 South Independence Mall West, Philadelphia, PA 19106-3483 for $50 annually for members and $120 for individual nonmembers. Clinical Cancer Research is only available to institutions as a combined subscription with Cancer Research. The combined 1998 institutional subscription price of $795 includes $210 for a subscription to Clinical Cancer Research. Periodicals postage paid at Philadelphia, PA and additional mailing offices. POSTMASTER: Send address changes to AACR Subscription Office, P.O. Box 11806, Birmingham, AL 35202. Copyright 1998 by the American Association for Cancer Research, Inc. Printed on acid-free paper in the U.S.A.
ASC0-JANSSEN RAS-RELATED TRANSLATIONAL RESEARCH GRANT PROGRAM

Janssen is pleased to announce that it has agreed to support an ASC0 Young Investigator Award with the intent to support research in the general area of signal transduction. ASCO's guidelines stress the importance of a goal to make the results ultimately clinically relevant.

The ability to understand signal transduction pathways will hopefully enable physicians to intervene at the fundamental cellular level in the disease process. This should result in drugs with greater efficacy and fewer adverse effects than conventional cytotoxic or hormonal anticancer therapy.

ASCO invites applications for a grant of $35,000 (total costs) of one year's duration. ASCO anticipates that a successful applicant may apply for a second year of support during the first year support. If the program is successful, it is anticipated that in subsequent years, additional applications will be sought.

This program is part of Janssen's commitment to the research and development of new anticancer agents.

ELIGIBILITY
Applications are encouraged from fellows and medical professionals in the field of oncology. Multiple submissions will be considered. However, each applicant may receive only one grant.

Applicants must be fellows of an academic institution with an identified sponsor (who is an ASCO member) and mentor. Applicants who are not active members of ASCO must apply for membership with the Society.

TIME TABLE

The application schedule is:
Deadline for receipt of applications ..................................November 13, 1998
Grant awarded ..........................................................May 1999 ASCO Annual Meeting

Applications will be reviewed by the ASCO Grants Selection Committee in February 1999. Notifications of acceptance are sent to applicants in mid-March 1999.

To receive the official Young Investigator Award application by mail, please contact:
American Society of Clinical Oncology
Department of Science and Education
225 Reinekers Lane, Suite 650
Alexandria, VA 22314
Phone: 703-299-1070 • Fax: 703-299-1044 • E-mail: ulepicl@asco.org

Applications must be received at the ASC0 headquarters on or before Friday, November 13, 1998.
Head, Breast Cancer for Medical Oncology—at the University of Maryland Greenebaum Cancer Center (UMGCC). Candidates must possess an outstanding record of accomplishment with qualifications to warrant appointment as associate or full professor in the Department of Medicine with a secondary appointment in the Program of Oncology at the Cancer Center. This is an exciting opportunity at an institution which has been expanding in an impressive way, both through the introduction of innovative clinical programs and a major emphasis on basic research. The UMGCC is strongly committed to the development of breast cancer programs. A substantial base in both basic and translational research support exists in the Cancer Center as a whole and in the breast program. This is an exciting environment for research, academic, and clinical growth, and there is tremendous potential for an individual with vision. The University of Maryland is an Affirmative Action/Equal Opportunity Employer. Please send curriculum vitae to John H. Moxley, III, M.D., Managing Director, Physician Executive Practice, Korn/Ferry International, 1800 Century Park East, Suite 900, Los Angeles, CA 90067.

Biologic Principles for the Therapy of Human Colon Cancer Conference
Marriott Coronado Island Resort, San Diego
November 5-8, 1998

The major goal of this conference is to review recent advances in the biology of human colon cancer that allow the development of new rational and effective therapies for colon cancer metastasis. New agents targeted toward these biologic alterations will be discussed. This conference will provide a forum for clinical investigators, basic researchers and scientists from academic institutions, pharmaceutical and biotechnology companies to exchange information useful to the development of new therapies. The logistics of collaborative research and translation of basic findings to the clinical reality will be addressed.

Conference Chairs: Lee Ellis, MD, Isaiah J. Fidler, DVM, PhD and James Abbruzzese, MD

For full conference information, please contact:
University of Texas MD Anderson Cancer Center
Office of Conference Services
Phone: 713/792-2222
Fax: 713/794-1724
http://www.mdacc.tmc.edu/-meetings

The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians. UTMD Anderson Cancer Center designates this educational activity for a maximum of 22.5 hours in Category 1 credit towards the AMA Physician’s Recognition Award.

National Cancer Institute
Division of Clinical Sciences

Patients Sought for Immunotoxin Studies

The National Cancer Institute (NCI) seeks patients for a new clinical study involving immunotoxin erb-38—a novel agent in which the variable regions of a monoclonal antibody against HER-2/neu have been linked to a truncated bacterial toxin. The reagent has been bioengineered to recognize the gene product of HER-2/neu.

Patients with breast, stomach, lung, ovarian, or colon cancer whose tumors express HER-2/neu are potential candidates. NCI will provide eligible patients with treatment and travel to the Clinical Center in Bethesda, Maryland. Please call the NCI Clinical Studies Support Center at 1-888-NCI-1937.